Heska Co. (NASDAQ:HSKA)’s share price hit a new 52-week high during trading on Monday . The stock traded as high as $217.83 and last traded at $216.03, with a volume of 776 shares trading hands. The stock had previously closed at $206.22.
Several brokerages have commented on HSKA. Alliance Global Partners increased their price target on shares of Heska from $230.00 to $240.00 and gave the company a “buy” rating in a research note on Friday, May 7th. Raymond James increased their price objective on Heska from $145.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday, February 25th. Piper Sandler increased their price objective on Heska from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Monday, May 10th. Finally, Zacks Investment Research raised Heska from a “sell” rating to a “hold” rating in a report on Monday, May 24th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $222.20.
The stock has a 50-day simple moving average of $191.09. The firm has a market cap of $2.31 billion, a PE ratio of -261.00 and a beta of 1.68. The company has a current ratio of 8.54, a quick ratio of 7.50 and a debt-to-equity ratio of 0.20.
Heska (NASDAQ:HSKA) last released its quarterly earnings data on Thursday, May 6th. The medical research company reported $0.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.35. The firm had revenue of $60.50 million during the quarter, compared to analysts’ expectations of $52.45 million. Heska had a positive return on equity of 0.77% and a negative net margin of 3.19%. The company’s revenue was up 97.7% compared to the same quarter last year. As a group, equities research analysts forecast that Heska Co. will post 0.4 earnings per share for the current fiscal year.
In other news, Director Sharon J. Larson sold 3,000 shares of the firm’s stock in a transaction on Monday, May 24th. The stock was sold at an average price of $205.00, for a total value of $615,000.00. Following the completion of the transaction, the director now owns 10,501 shares in the company, valued at $2,152,705. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Nancy Wisnewski sold 5,000 shares of the firm’s stock in a transaction on Friday, June 4th. The shares were sold at an average price of $197.87, for a total value of $989,350.00. Following the completion of the transaction, the chief operating officer now owns 59,998 shares of the company’s stock, valued at approximately $11,871,804.26. The disclosure for this sale can be found here. Corporate insiders own 8.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in HSKA. Altshuler Shaham Ltd purchased a new position in shares of Heska in the first quarter valued at $38,000. Dorsey Wright & Associates increased its position in Heska by 138.1% during the 1st quarter. Dorsey Wright & Associates now owns 269 shares of the medical research company’s stock worth $45,000 after purchasing an additional 156 shares in the last quarter. Benjamin F. Edwards & Company Inc. purchased a new stake in Heska during the 1st quarter worth about $50,000. Sowell Financial Services LLC purchased a new stake in Heska during the 1st quarter worth about $61,000. Finally, Veriti Management LLC purchased a new stake in Heska during the 4th quarter worth about $62,000. Institutional investors and hedge funds own 94.88% of the company’s stock.
Heska Company Profile (NASDAQ:HSKA)
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
See Also: Initial Public Offering (IPO)
